Reaktionsgleichung
[CH3:1][O:2][CH2:3][C:4]1[CH:9]=[C:8]([C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:16]=[C:17]([CH:21]=[CH:22][CH:23]=3)[C:18](Cl)=[O:19])[N:11]=2)[CH:7]=[CH:6][C:5]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][C:25]=1[CH3:30].Cl.[CH3:32][O:33][C:34](=[O:37])[CH2:35][NH2:36]>>[CH3:1][O:2][CH2:3][C:4]1[CH:9]=[C:8]([C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:16]=[C:17]([CH:21]=[CH:22][CH:23]=3)[C:18]([NH:36][CH2:35][C:34]([O:33][CH3:32])=[O:37])=[O:19])[N:11]=2)[CH:7]=[CH:6][C:5]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][C:25]=1[CH3:30]Komponenten
Versuchsvorschrift
3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl chloride was prepared following procedure described in example 116 starting from example 92. It was obtained as an oil (1070 mg, 96%). The title compound was prepared following procedure described in example 121 starting from 3-{5-[2-(methoxymethyl)-2′-methylbiphenyl-4-yl]-1,2,4-oxadiazol-3-yl}benzoyl chloride and glycine methyl ester hydrochloride. The title compound was obtained as a pale yellow powder (97 mg, 86%). 1H NMR: (DMSO-d6, 300 MHz) δ 9.27 (m, 1H), 8.63 (m, 1H), 8.35 (m, 1H), 8.31 (m, 1H), 8.19 (dd, J=1.8 Hz, 7.9 Hz, 1H), 8.12 (m, 1H), 7.76 (t, J=7.9 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.39-7.26 (m, 3H), 7.15 (m, 1H), 4.23 (d, J=12.9 Hz, 1H), 4.17 (d, J=12.9 Hz, 1H), 4.07 (d, J=5.8 Hz, 1H), 3.68 (s, 3H), 3.25 (s, 3H), 2.04 (s, 3H). LC/MS (Method B): 472.2 (M+H)+ 470.2 (M−H)−. HPLC (Method A) Rt: 4.92 min (purity: 99.2%).
Aufarbeitung
- customThe title compound was prepared following procedure
Quellen und Nachweise
- ORD-Eintrag
- ord-6206a789203f428784e7d34b0ee6d61d
- Quelldatensatz
- uspto-grants-2012_06
- Patentnummer
- US08202865B2
Verknüpfte Notizen
Wird geladen…